Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeRenalogicCareINSIGHTS.ai Introduced: 1st of Its Kind Clinical Intervention Program Powered by AI-based...

CareINSIGHTS.ai Introduced: 1st of Its Kind Clinical Intervention Program Powered by AI-based Predictive Modeling

November 19, 2020

CareINSIGHTS.ai was introduced today by Renalogic. CareINSIGHTS.ai is the first of its kind, clinical intervention program that is powered by AI-based predictive modeling, and is proven to help bend the catastrophic claims cost curve.

CareINSIGHTS.ai is the industry’s most advanced kidney care management program combining intelligence with tailored intervention to reduce the associated risk.

“We’re putting an end to surprise dialysis claims and changing the prognosis while reducing the hidden risk associated with CKD,” Mark Masson, President at Renalogic said. “The shift to identifying previously hidden risk results in a new, higher standard of chronic condition management. Today, we are identifying future CKD risk earlier than anyone else. CareINSIGHTS.ai can accurately predict when individuals will progress to higher acuity stages of chronic kidney disease and when they will progress to dialysis without proper intervention. This enables us to control future risk and provide the right care at the right time. We are helping to avoid growing claims costs associated with CKD and dialysis.”

CareINSIGHTS.ai arrives at a time when CKD continues to be the third-highest medical claims cost category. In 2020, estimated claims cost associated with CKD, which is often referred to as “the silent epidemic,” will total over $100 billion for commercial health plans. With new predictive modeling and AI, using hundreds of dimensions of data, CareINSIGHTS.ai can accurately predict each plan member’s propensity to advance to the next stage of CKD, including dialysis within the next 12 months. That’s every member, even those without a CKD diagnosis. This makes it possible to avoid the risk associated with CKD and dialysis, by delivering personalized intervention based on much more than the member’s CKD stage, including their trajectory and expected progression toward dialysis.

For more than a decade, Renalogic has been using data to mitigate CKD and dialysis risk. Now, CareINSIGHTS.ai is the next evolution of predictive modeling powered by AI. CareINSIGHTS.ai reports with 90% accuracy in identifying where and when CKD and dialysis claims will appear in the future. Over time, the predictive modeling will improve as it continues to think and learn as a “doctor.”

CareINSIGHTS.ai gives health plan administrators a look into future healthcare claims costs and utilization. “When we know what’s coming, we have time to avoid an emergent start to dialysis,” Masson said. Renalogic, a pioneer in dialysis cost containment, is again leading the industry by adopting a modern, AI-driven approach. “By taking the guesswork out of hidden risk, we’re giving health plan fiduciaries an extraordinary advantage compared to other dialysis cost containment options. CareINSIGHTS.ai layers claims cost containment and cost avoidance. What’s more, the proprietary predictive intelligence indicates future plan needs and could present additional savings for plans year over year.”

The Renalogic* Kidney Dialysis Avoidance Program (KDAP) successfully slows, stops and even reverses the progression of CKD. Nearly 80% of active KDAP members who have participated for six months or more have maintained or improved their CKD disease state. CareINSIGHTS.ai identifies additional risk earlier, identifies gaps in care and the leading indicator for each member’s trajectory toward dialysis. This makes personalized intervention as unique as each member’s fingerprint a reality for Renalogic clients.

Renalogic notes: For nearly two decades, we continue to be proud, forward-thinking leaders in a niche industry that is in crisis. We are an ambitious disruptor driving positive change to contain the catastrophic costs of dialysis. We are changing the way plan administrators think about dialysis. Chronic Kidney Disease (CKD) costs are an epidemic issue that will not resolve on its own. The logical approach is to get ahead of the curve. We are one company, one cause, leading the industry by empowering our clients to avoid dialysis altogether with solutions and technology for kidney disease management. No one does what we do. We exist to open minds, achieve sustainable results for our clients and be an advocate for kidney disease management, dialysis cost containment and prevention.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy